Latest Drug Delivery News

Page 4 of 6
Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.
Ada Torres
Ada Torres
17 Nov 2025
Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.
Ada Torres
Ada Torres
5 Nov 2025
Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.
Ada Torres
Ada Torres
31 Oct 2025
Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.
Ada Torres
Ada Torres
31 Oct 2025
Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.
Ada Torres
Ada Torres
30 Oct 2025
Starpharma has secured a $5.5 million upfront payment from Genentech as part of a new collaboration to develop dendrimer-drug conjugates targeting cancer therapies. The partnership includes potential milestone payments exceeding half a billion dollars and tiered royalties.
Ada Torres
Ada Torres
22 Oct 2025
PYC Therapeutics has kicked off a global Phase 1b repeat dose study of its investigational drug PYC-001 targeting Autosomal Dominant Optic Atrophy, a rare genetic eye disease with no current treatments. Initial dosing has begun, with key data expected in the second half of 2026.
Ada Torres
Ada Torres
21 Oct 2025
LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.
Victor Sage
Victor Sage
6 Oct 2025
Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.
Ada Torres
Ada Torres
22 Sept 2025
Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.
Ada Torres
Ada Torres
22 Sept 2025
Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.
Ada Torres
Ada Torres
29 Aug 2025
LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.
Ada Torres
Ada Torres
29 Aug 2025

Browse the archive

Full archive